Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Expands By 37.3%

Tharimmune, Inc. (NASDAQ:THAR) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 103,400 shares, a growth of 37.3% from the March 31st total of 75,300 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily volume of 488,400 shares, the short-interest ratio is currently 0.2 days.

Tharimmune Trading Up 2.2 %

Shares of THAR stock opened at $0.37 on Monday. Tharimmune has a 1 year low of $0.34 and a 1 year high of $31.50. The firm’s 50 day moving average is $0.40 and its 200-day moving average is $1.38. The firm has a market capitalization of $4.33 million, a price-to-earnings ratio of -0.02 and a beta of 1.63.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).